v3.25.2
License and Collaboration Agreement with ImmuneOnco
6 Months Ended
Jun. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
License and Collaboration Agreement with ImmuneOnco License and Collaboration Agreement with ImmuneOnco
On August 1, 2024, Axion Bio entered into the IO Collaboration Agreement with ImmuneOnco, under which it in-licensed several bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M. As part of this agreement, Axion Bio made a $10.0 million upfront payment to ImmuneOnco during the year ended December 31, 2024. This amount was fully expensed as in-process research and development (IPR&D) in the same year.
ImmuneOnco is eligible to receive additional potential near-term payments of up to $20.0 million, up to $2.1 billion in commercial, development and regulatory milestones (including up to $270.0 million in longer term development and regulatory milestones and up to $1.8 billion in commercial milestones) plus single-digit to low double-digit percentage royalties on global net sales of the licensed products outside of Greater China.
During the year ended December 31, 2024, Axion Bio made a $5.0 million prepayment for development costs, which was fully expensed as of March 31, 2025. A second $5.0 million prepayment for development costs was made
in April 2025. This amount was partially expensed under research and development, with a remaining prepaid balance of $0.7 million recorded as of June 30, 2025.
During the quarter ended June 30, 2025, Axion Bio achieved Investigational New Drug (IND) clearance in the United States for a Phase 1 trial of AXN-2510 in relapsed/refractory solid tumors. This milestone triggered a $10.0 million development payment, which was accrued as of June 30, 2025. This amount was fully expensed as IPR&D in the three and six months ended June 30, 2025.
The expenses recognized in connection with the IO Collaboration Agreement were $14.1 million and nil for the three months ended June 30, 2025 and 2024, respectively, and $18.4 million and nil for the six months ended June 30, 2025 and 2024, respectively, and were recorded as a component of research and development expense on the condensed consolidated statements of operations and comprehensive loss.